Literature DB >> 15679639

Acute and long-term results of slow pathway ablation in patients with atrioventricular nodal reentrant tachycardia--an analysis of the predictive factors for arrhythmia recurrence.

Heidi Luise Estner1, Gjin Ndrepepa, Jun Dong, Isabel Deisenhofer, Juergen Schreieck, Michael Schneider, Andreas Plewan, Martin Karch, Sonja Weyerbrock, Diana Wade, Bernhard Zrenner, Claus Schmitt.   

Abstract

BACKGROUND: Predictors of atrioventricular nodal reentrant tachycardia (AVNRT) recurrence after radiofrequency ablation including the importance of residual slow pathway conduction are not known. The aim of this study was to report the acute and long-term results of slow pathway ablation in a large series of consecutive patients with AVNRT and to analyze the potential predictors of arrhythmia recurrence with a particular emphasis on the residual slow pathway conduction after ablation.
METHODS: The study included 506 consecutive patients with AVNRT (mean age 52.6 +/- 16 years, 315 women) who underwent slow pathway ablation using a combined electrophysiological and anatomical approach. The end point of ablation procedure was noninducibility of the arrhythmia. The primary end point of the study was the recurrence of AVNRT.
RESULTS: Acute success was achieved in 500 patients (98.8%). After ablation, 471 patients (93%) were followed up for a mean of 903 +/- 692 days. Of the 465 patients with successful ablation, 24 patients (5.2%) developed AVNRT recurrences during the follow-up. No significant differences in the cumulative rates of AVNRT recurrence were observed in groups with or without electrophysiological evidence of residual slow pathway conduction (P = 0.25, log-rank test). Multivariate analysis identified only age as an independent predictor of AVNRT recurrence (hazard ratio 0.96, 95% confidence interval 0.94-0.99, P = 0.004) with younger patients being at an increased risk for arrhythmia recurrence.
CONCLUSIONS: Our study demonstrated that only younger age, but not other clinical or electrophysiological parameters including residual slow pathway conduction predicted an increased risk for AVNRT recurrence after slow pathway radiofrequency ablation.

Entities:  

Mesh:

Year:  2005        PMID: 15679639     DOI: 10.1111/j.1540-8159.2005.09364.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  12 in total

1.  Determinants of immediate success for catheter ablation of atrioventricular nodal reentry tachycardia in patients without junctional rhythm.

Authors:  Ataallah Bagherzadeh; Tooraj Keshavarzi; Maryam Moshkani Farahani; Hamidreza Goodarzynejad
Journal:  J Interv Card Electrophysiol       Date:  2013-10-08       Impact factor: 1.900

2.  Role of isoproterenol in predicting the success of catheter ablation in patients with reproducibly inducible atrioventricular nodal reentrant tachycardia.

Authors:  Alireza Heydari; Mohammad Tayyebi; Rahmatolah Damanpak Jami; Asgar Amiri
Journal:  Tex Heart Inst J       Date:  2014-06-01

3.  Multicenter, randomized comparison between magnetically navigated and manually guided radiofrequency ablation of atrioventricular nodal reentrant tachycardia (the MagMa-AVNRT-trial).

Authors:  Tilko Reents; Clemens Jilek; Peter Schuster; Georg Nölker; Katharina Koch-Büttner; Sonia Ammar-Busch; Verena Semmler; Felix Bourier; Marc Kottmaier; Marie Kornmayer; Stephanie Brooks; Stephanie Fichtner; Christof Kolb; Isabel Deisenhofer; Gabriele Hessling
Journal:  Clin Res Cardiol       Date:  2017-08-28       Impact factor: 5.460

4.  Cryoablation therapy for atrioventricular nodal reentrant tachycardia in children: a multicenter experience of efficacy.

Authors:  Srikant Das; Ian H Law; Nicholas H Von Bergen; David J Bradley; Macdonald Dick; Susan P Etheridge; Elizabeth V Saarel; Patricio A Frias; Margaret J Strieper; Peter S Fischbach
Journal:  Pediatr Cardiol       Date:  2012-03-20       Impact factor: 1.655

5.  Occurrence of primarily noninducible atrioventricular nodal reentry tachycardia after radiofrequency delivery in the slow pathway region during empirical slow pathway modulation.

Authors:  Felix Konrad Wegner; Nils Bögeholz; Patrick Leitz; Gerrit Frommeyer; Dirk Georg Dechering; Simon Kochhäuser; Philipp Sebastian Lange; Julia Köbe; Kristina Wasmer; Gerold Mönnig; Lars Eckardt; Christian Pott
Journal:  Clin Cardiol       Date:  2017-11-22       Impact factor: 2.882

6.  Outcome of slow pathway modulation for atrioventricular nodal reentrant tachycardia with 50 versus 30 watts-more power, more effect?

Authors:  Dirk G Dechering; Ruben Schleberger; Eva Greiser; Jannis Dickow; Julia Koebe; Gerrit Frommeyer; Stephan Willems; Lars Eckardt; Boris A Hoffmann; Kristina Wasmer
Journal:  J Interv Card Electrophysiol       Date:  2018-03-19       Impact factor: 1.900

7.  Recurrent supraventricular tachycardias prevalence and pathophysiology after RF ablation: A 5-year registry.

Authors:  Khaled Hussien; Mohamed Hammouda; Hazem Elakbawy; Ahmed Abdelaziz; Ahmed Abdelaal; Mohamed Shehata; El Shazly Abdelkhalik; Hassan Nagi; Sherif Mokhtar
Journal:  J Saudi Heart Assoc       Date:  2009-10

8.  Value of an old school approach: safety and long-term success of radiofrequency current catheter ablation of atrioventricular nodal reentrant tachycardia in children and young adolescents.

Authors:  Henrike Siebels; Christian Sohns; Jan-Hendrik Nürnberg; Jürgen Siebels; Klaus Langes; Joachim Hebe
Journal:  J Interv Card Electrophysiol       Date:  2018-05-15       Impact factor: 1.900

9.  Prediction of Primary Slow-Pathway Ablation Success Rate according to the Characteristics of Junctional Rhythm Developed during the Radiofrequency Catheter Ablation of Atrioventricular Nodal Reentrant Tachycardia.

Authors:  Ataallah Bagherzadeh; Mohammad Esmaeel Rezaee; Maryam Moshkani Farahani
Journal:  J Tehran Heart Cent       Date:  2011-02-28

10.  Double Ventricular Responses Leading to Reversible Cardiomyopathy as Late Complication after Slow-Pathway Ablation.

Authors:  Umut Celikyurt; Meinrad Gawaz; Juergen Schreieck; Peter Seizer
Journal:  Case Rep Cardiol       Date:  2015-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.